logo

For the Inventor, By the Inventor

Gehrden, Germany

Dagmar Hoeltje

This inventor holds 11 USPTO granted patents and 1 published patent application. Top assignees: Solvay Pharmaceuticals, Gmbh, Beecham-Wuelfing Gmbh & Co. Kg, Beecham-Wuelfing Gmbh & Co.. Active years: 1989-2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dagmar Hoeltje. Retrieved from https://idiyas.com/inventor/dagmar-hoeltje

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 11 

% Patents Active = 72.7

Average Co-Inventor Count = 3.7

ph-index = 4

Forward Citations = 135(Granted Patents)


Location History:

  • Gronau, DE (1989 - 1995)
  • Gehrden, DE (1997 - 2008)

Company Filing History:

goldMedal6 out of 77 
 
Solvay Pharmaceuticals, Gmbh
 patents
silverMedal3 out of 10 
 
Beecham-Wuelfing Gmbh & Co. Kg
 patents
bronzeMedal1 out of 1 
 
Beecham-Wuelfing Gmbh & Co.
 patent
4. 1 out of 92 
 
Kali-Chemie Pharma Gmbh
 patents

Years Active: 1989-2008

Loading Chart...
11 patents (USPTO):Explore Patents
1. 7452875 - Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them (2008-11-18),
2. 7427611 - Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them (2008-09-23),
3. 7410962 - Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them (2008-08-12),
4. 7262184 - Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them (2007-08-28),
5. 5912235 - 10, 13, 15-trioxatricyclo �9.2.1.1..sup.9.6 !-pentadecan one (1999-06-15),
6. 5677297 - Benzazepine-, benzoxazepine- and benzothiazepine-n-acetic acid (1997-10-14),
7. 5418224 - 4,13-dioxabicyclo[8.2.1]tridecenone compounds and pharmaceutical (1995-05-23),
8. 4987137 - Certain 6,7,8,9-tetrahydropyrido[1,2-.alpha.]indoles and their use for (1991-01-22),
9. 4980368 - Tryptamine compounds, and methods of cerebrovascular treatment therewith (1990-12-25),
10. 4968699 - Pyrido[1,2-a]indoles and their use as CNS agents (1990-11-06),
11. 4835271 - Aminoalkyl secocanthine derivatives and their use (1989-05-30),

Title: Dagmar Hoeltje: Innovator in Pharmaceutical Compounds

Introduction

Dagmar Hoeltje is a prominent inventor based in Gehrden, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have therapeutic applications.

Latest Patents

Dagmar Hoeltje holds a total of 11 patents. Her latest patents include Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds. These compounds exhibit neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity. They are particularly relevant for treating or inhibiting cardiovascular diseases, sexual dysfunction, and adverse conditions associated with apoptosis.

Career Highlights

Throughout her career, Dagmar has worked with notable companies such as Solvay Pharmaceuticals GmbH and Beecham-Wuelfing GmbH & Co. KG. Her work has significantly impacted the pharmaceutical industry, leading to advancements in drug development.

Collaborations

Dagmar has collaborated with esteemed colleagues, including Josef Messinger and Dietrich Thielke. These partnerships have fostered innovation and contributed to her success in the field.

Conclusion

Dagmar Hoeltje's work in pharmaceutical innovations showcases her dedication to improving health outcomes through her inventions. Her contributions continue to influence the industry and pave the way for future advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…